Nevertheless, further studies were validated not only because there were indications that a subset of patients with moderately severe COPD might have benefitted by oxygen supplementation but also ...

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

BARCELONA -- The need for antibiotics in patients with chronic obstructive pulmonary disease (COPD) seeking treatment for moderate acute COPD exacerbations could not be ruled out in a randomized trial ...

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe COPD experienced improvements with 3 mg of twice-daily ensifentrine. Study ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

The clinical and survival benefit of home oxygen therapy, both LTOT and nocturnal oxygen therapy, for patients with COPD and moderate hypoxemia was evaluated in this meta-analysis. Home oxygen therapy ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

According to a recent study, patients with an exacerbation of chronic obstructive pulmonary disease (COPD) have greater risks of both subsequent exacerbations and mortality. The odds of subsequent ...

Researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is vs DPP-4is and among those treated with GLP-1 RAs vs DPP-4is. HealthDay News — For ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...